



**U. S. DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Application Number	Filing Date	First Named Applicant	Attorney Docket Number
09/339,818	06/25/99	Davis	038134-50010

Examiner
L. E. Crane

Art Unit	Paper No.
1623	16

DATE MAILED: n/a

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel)

- (1) Mr. Jeffrey A. Lindeman (3) --
(2) Examiner L. E. Crane (4) --

Date of Interview: 11/06/01

Type ☒ Telephonic ☐ Personal (copy given to) ☐ applicant ☐ applicant's representative

Exhibit shown or demonstration conducted: ☐ Yes ☒ No If yes, brief description: See attachment.

Agreement ☒ was reached with respect to some of all of the claims in question. ☐ was not reached

Claim(s) discussed: See page 2.

Identification of prior art discussed: See page 2.

Description of the general nature of what was agreed to if an agreement was reached, or any other comment: See p. 2.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would be allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☒ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP § 713.04) If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, the completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign this form unless it is an attachment to another form.

PTOL-413 (amended 03/13/01)

09/339,818 - P. N. 16 COPY FOR [X] File [] Applicant Continued on next page(s) ->>

Serial No. **09/339,818**

2

Art Unit 1623

INTERVIEW SUMMARY(cont.)

Claims discussed: All remaining of record, claims **8, 9, 10, 31, 44, 50 and 56-57** in particular.

Identification of prior art discussed: **NONE.**

Description of the general nature of what was agreed to if an agreement was reached, or any other comment: Applicant was advised that minor errors in the noted claims required correction. Applicant agreed to the suggested changes, authorized an examiner's amendment, and was informed that the claims as finally amended were now allowable and would be passed to issue in due course.



United States Patent and Trademark Office

TELECOPY/FACSIMILE TRANSMISSION (FAX)

GROUP 1600, Art Unit 1623

Date: November 6, 2001.

Number of Pages 05, Including This Page.

To: Mr/ Jeffrey A. Lindeman (Attny./Agent)

038134-50010 || 09/339,818 (Attny Docket No./Application No.)

Morgan, Lewis & Brokius (Organization/Firm/Agency)

9-1-202-467-7176 (FAX/Telecopier Number)

From: Examiner L. E. Crane, Art Unit 1623.

Art Unit 1600's FAX machine may be accessed at (703) 308-4556.

Examiner's Office Phone No.: (703) 308-4639. If you have not received all pages of this transmission, please contact the Examiner at the above telephone number.

All FAX machines will be available to receive transmissions 24 hours/day, 7 days/week.

If you have not received all pages of this transmission and cannot reach the Examiner, please contact this Office as soon as possible at one of the following telephone numbers:

The Examiner's supervisor, Mr. Gary Geist, may be reached at (703) 308-1701.

The Group 1600 receptionist may be reached at (703) 308-1235.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE'S STAMPED DATE FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

Art Unit 1623

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group 1600, Art Unit 1623.

5 An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. §1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

10 In claim 8, after the term "claim 1," the term
-- further comprising -- was inserted.

 In claim 9, after the term "claim 8," the term
-- further comprising -- was inserted.

15 In claim 9, the following term was inserted between the last term
and the terminal punctuation:
-- ; wherein said ligand allows the attached linear cyclodextrin to target
and bind to a cell -- .

 In claim 10, after the term "claim 1," the term
-- further comprising -- was inserted.

20 In claim 10, the following term was inserted between the last term
and the terminal punctuation:
-- ; wherein said ligand allows the attached linear cyclodextrin to target
and bind to a cell -- .

Art Unit 1623

In claim 31, the following term was inserted between the last term and the terminal punctuation:

-- ; wherein said ligand allows the attached linear cyclodextrin to target and bind to a cell -- .

5 In claim 44 at line 1, the term "therapeutic" was amended to read -- therapeutic agent --.

In claim 50 at line 1, the term "therapeutic" was amended to read -- therapeutic agent --.

10 In claim 56, the following term was inserted between the last term and the terminal punctuation:
-- ; wherein said ligand allows the attached linear cyclodextrin to target and bind to a cell -- .

In claim 57 at line 1, the term "therapeutic" was amended to read -- therapeutic agent --.

15 Authorization for this Examiner's Amendment was given in a telephone interview with **Mr. Jeffrey A. Lindeman** on November 6, 2001

20 Papers related to this application may be submitted to Group 1600 via facsimile transmission(FAX). The transmission of such papers must conform with the notice published in the Official Gazette (1096 OG 30, November 15, 1989). The telephone number for the FAX machine now operated by Group 1600 is **703-308-4556**.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner L. E.

Art Unit 1623

Crane whose telephone number is **703-308-4639**. The examiner can normally be reached between 9:30 AM and 5:00 PM, Monday through Friday.

5 If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Gary Geist, can be reached on **703-308-1701**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is **703-308-1235**.

10 All Post-Allowance Correspondence concerning this application must be mailed to:

BOX ISSUE FEE
COMMISSIONER FOR PATENTS
15 WASHINGTON, DC 20231

OR you can FAX them to the Office of Patent Publications at 703-308-5083, in order to expedite the handling of such correspondence as amendments under 37 C.F.R. §1.312; Information Disclosure Statements (IDS's), and formal drawings. Sending Post-Allowance papers to
20 Technology Center 1600 will only cause delays in matching papers with the case.

For information concerning status of correspondence sent after receipt of the Notice of Allowance, please contact the Correspondence
25 Branch at **703-305-8027**. The Notice of Allowance also has an insert containing contact information of other items, including Issue Fees,

Serial No. **09/339,818**

5

Art Unit 1623

receipt of formal drawings, and the status of the application.

LECrane:lec

11/06/01